These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 27594341

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Levosimendan, a calcium sensitizer in cardiac muscle, induces relaxation in coronary smooth muscle through calcium desensitization.
    Bowman P, Haikala H, Paul RJ.
    J Pharmacol Exp Ther; 1999 Jan; 288(1):316-25. PubMed ID: 9862786
    [Abstract] [Full Text] [Related]

  • 3. Levosimendan (OR-1259), a myofilament calcium sensitizer, enhances myocardial contractility but does not alter isovolumic relaxation in conscious and anesthetized dogs.
    Pagel PS, Harkin CP, Hettrick DA, Warltier DC.
    Anesthesiology; 1994 Oct; 81(4):974-87. PubMed ID: 7943849
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ, Domínguez Rodríguez A.
    Am J Cardiovasc Drugs; 2006 Oct; 6(2):69-75. PubMed ID: 16555860
    [Abstract] [Full Text] [Related]

  • 5. Levosimendan.
    Figgitt DP, Gillies PS, Goa KL.
    Drugs; 2001 Oct; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA.
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [Abstract] [Full Text] [Related]

  • 14. Is calcium sensitization the best strategy to improve myocardial contractility in acute heart failure?
    Erhardt LR.
    Ital Heart J; 2003 May; 4 Suppl 2():27S-33S. PubMed ID: 14635367
    [Abstract] [Full Text] [Related]

  • 15. Effects of a myofilament calcium sensitizer on left ventricular systolic and diastolic function in rats with volume overload heart failure.
    Wilson K, Guggilam A, West TA, Zhang X, Trask AJ, Cismowski MJ, de Tombe P, Sadayappan S, Lucchesi PA.
    Am J Physiol Heart Circ Physiol; 2014 Dec 01; 307(11):H1605-17. PubMed ID: 25260618
    [Abstract] [Full Text] [Related]

  • 16. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F.
    Ital Heart J; 2003 May 01; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [Abstract] [Full Text] [Related]

  • 17. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
    Banfor PN, Preusser LC, Campbell TJ, Marsh KC, Polakowski JS, Reinhart GA, Cox BF, Fryer RM.
    Am J Physiol Heart Circ Physiol; 2008 Jan 01; 294(1):H238-48. PubMed ID: 17982006
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A, Lebrin M, Vaccaro A, Senard JM, Despas F.
    J Clin Pharm Ther; 2013 Oct 01; 38(5):341-9. PubMed ID: 23594161
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.